Regulation of vascular endothelial growth factor in prostate cancer

Endocrine-Related Cancer

Volumn 22, Issue 3, 2015, Pages R107-R123

  De Brot, Simone ^a   Ntekim, Atara ^a   Cardenas, Ryan ^a   James, Victoria ^a   Allegrucci, Cinzia ^a   Heery, David M ^b   Bates, David O ^c   Ødum, Niels ^d   Persson, Jenny L ^e   Mongan, Nigel P ^a,f  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^c UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

^e LUND UNIVERSITY   (Sweden)

^f WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Androgen; Angiogenesis; Animal model; Castration resistant prostate cancer; Neuroendocrine; Transcription; Xenograft

Indexed keywords

ANDROGEN; ANGIOGENESIS INHIBITOR; VASCULOTROPIN; VASCULOTROPIN A;

ANGIOGENESIS; ANTIANGIOGENIC THERAPY; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CARCINOGENESIS; CELL INTERACTION; ENZYME REGULATION; GENETIC TRANSCRIPTION; HUMAN; MALE; MOUSE MODEL; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; PROSTATE CANCER CELL LINE; REVIEW; SIGNAL TRANSDUCTION; THERAPY EFFECT; ANIMAL; CASTRATION RESISTANT PROSTATE CANCER; DRUG SCREENING; METABOLISM; PATHOLOGY; PROSTATE TUMOR;

ANIMALS; HUMANS; MALE; PROSTATIC NEOPLASMS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84937040234     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-15-0123     Document Type: Review

References (169)

1. Ahmed A, Ali S & Sarkar FH 2014 Advances in androgen receptor targeted therapy for prostate cancer. Journal of Cellular Physiology 229 271-276.(doi:10.1002/jcp.24456)
2. Akiri G, Nahari D, Finkelstein Y, Le SY, Elroy-Stein O & Levi BZ 1998 Regulation of vascular endothelial growth factor (VEGF) expression is mediated by internal initiation of translation and alternative initiation of transcription. Oncogene 17 227-236. (doi:10.1038/sj.onc.1202019)
3. Anai S, Sakamoto N, Sakai Y, Tanaka M, Porvasnik S, Urbanek C, Cao W, Goodison S & Rosser CJ 2011 Dual targeting of Bcl-2 and VEGF: a potential strategy to improve therapy for prostate cancer. Urologic Oncology 29 421-429. (doi:10.1016/j.urolonc.2009.04.009)
4. Arcondeguy T, Lacazette E, Millevoi S, Prats H & Touriol C 2013 VEGF-A mRNA processing, stability and translation: a paradigm for intricate regulation of gene expression at the post-transcriptional level. Nucleic Acids Research 41 7997-8010. (doi:10.1093/nar/gkt539)
5. Armstrong AJ, Haggman M, Stadler WM, Gingrich JR, Assikis V, Polikoff J, Damber JE, Belkoff L, Nordle O, Forsberg G et al. 2013 Long-term survival and biomarker correlates of tasquinimod efficacy in a multicenter randomized study of men with minimally symptomatic metastatic castration-resistant prostate cancer. Clinical Cancer Research 19 6891-6901. (doi:10.1158/1078-0432.CCR-13-1581)
6. Asangani IA, DommetiVL, WangX, Malik R, CieslikM, YangR, Escara-Wilke J, Wilder-Romans K, Dhanireddy S, Engelke C et al. 2014 Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer. Nature 510 278-282. (doi:10.1038/nature13229)
7. Auboeuf D, Honig A, Berget SM & O'Malley BW 2002 Coordinate regulation of transcription and splicing by steroid receptor coregulators. Science 298 416-419. (doi:10.1126/science.1073734)
8. Auboeuf D, DowhanDH, KangYK, LarkinK, LeeJW, Berget SM&O'MalleyBW 2004 Differential recruitment of nuclear receptor coactivators may determine alternative RNA splice site choice in target genes. PNAS 101 2270-2274. (doi:10.1073/pnas.0308133100)
9. Baca SC, Prandi D, LawrenceMS, Mosquera JM, Romanel A, Drier Y, Park K, Kitabayashi N, MacDonald TY, Ghandi M et al. 2013 Punctuated evolution of prostate cancer genomes. Cell 153 666-677. (doi:10.1016/j.cell.2013.03.021)
10. Barbieri CE, Baca SC, Lawrence MS, Demichelis F, BlattnerM, Theurillat JP, White TA, Stojanov P, Van Allen E, Stransky N et al. 2012 Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nature Genetics 44 685-689. (doi:10.1038/ng.2279)
11. Barbieri CE, Bangma CH, Bjartell A, Catto JW, Culig Z, Gronberg H, Luo J, Visakorpi T & Rubin MA 2013 The mutational landscape of prostate cancer. European Urology 64 567-576. (doi:10.1016/j.eururo.2013.05.029)
12. Bates DO, Cui DG, Doughty JM, Winkler M, Sugiono M, Shields JD, Peat D, Gillatt D & Harper SJ 2002 VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma. Cancer Research 62 4123-4131.
13. Beltran H, Rickman DS, Park K, Chae SS, Sboner A, MacDonald TY, Wang Y, Sheikh KL, Terry S, Tagawa ST et al. 2011 Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets.Cancer Discovery 1 487-495. (doi:10.1158/2159-8290.CD-11-0130)
14. Berger MF, Lawrence MS, Demichelis F, Drier Y, Cibulskis K, Sivachenko AY, Sboner A, Esgueva R, Pflueger D, Sougnez C et al. 2011 The genomic complexity of primary human prostate cancer. Nature 470 214-220. (doi:10.1038/nature09744)
15. Berman-Booty LD & Knudsen KE 2015 Models of neuroendocrine prostate cancer. Endocrine-Related Cancer22 R33-R49. (doi:10.1530/ERC-14-0393)
16. Boll K, ReicheK, KasackK, Morbt N, Kretzschmar AK, TommJM, Verhaegh G, Schalken J, von Bergen M, Horn F et al. 2013 MiR-130a, miR-203 and miR-205 jointly repress key oncogenic pathways and are down-regulated in prostate carcinoma. Oncogene 32 277-285. (doi:10.1038/onc.2012.55)
17. deBono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, ChiK N, Jones RJ, Goodman OB Jr, Saad F et al. 2011 Abiraterone and increased survival in metastatic prostate cancer. New England Journal of Medicine 364 1995-2005. (doi:10.1056/NEJMoa1014618)
18. Boorjian SA, Eastham JA, Graefen M, Guillonneau B, Karnes RJ, Moul JW, Schaeffer EM, Stief C & Zorn KC 2012 A critical analysis of the long-term impact of radical prostatectomy on cancer control and function outcomes.European Urology 61 664-675. (doi:10.1016/j.eururo.2011.11.053)
19. Burton JB, Priceman SJ, Sung JL, Brakenhielm E, An DS, Pytowski B, Alitalo K & Wu L 2008 Suppression of prostate cancer nodal and systemic metastasis by blockade of the lymphangiogenic axis. Cancer Research 68 7828-7837. (doi:10.1158/0008-5472.CAN-08-1488)
20. Buteau-Lozano H, Ancelin M, Lardeux B, Milanini J & Perrot-Applanat M 2002 Transcriptional regulation of vascular endothelial growth factor by estradiol and tamoxifen in breast cancer cells: a complex interplay between estrogen receptors a and b. Cancer Research 62 4977-4984.
21. Cai C, He HH, Chen S, Coleman I, Wang H, Fang Z, Nelson PS, Liu XS, BrownM& Balk SP 2011 Androgen receptor gene expression in prostate cancer is directly suppressed by the androgen receptor through recruitment of lysine-specific demethylase 1. Cancer Cell 20 457-471.(doi:10.1016/j.ccr.2011.09.001)
22. Cai C, He HH, Gao S, Chen S, Yu Z, Gao Y, Chen MW, Zhang J, Ahmed M, Wang Y et al. 2014 Lysine-specific demethylase 1 has dual functions as a major regulator of androgen receptor transcriptional activity. Cell Reports 9 1618-1627. (doi:10.1016/j.celrep.2014.11.008)
23. Campbell RM & Tummino PJ 2014 Cancer epigenetics drug discovery and development: the challenge of hitting the mark. Journal of Clinical Investigation 124 64-69. (doi:10.1172/JCI71605)
24. Cardus A, Panizo S, Encinas M, Dolcet X, Gallego C, Aldea M, Fernandez E & Valdivielso JM 2009 1, 25-dihydroxyvitamin D3 regulates VEGF production through a vitamin D response element in the VEGF promoter. Atherosclerosis 204 85-89. (doi:10.1016/j.atherosclerosis. 2008.08.020)
25. Carmeliet P&Jain RK 2011Molecular mechanisms and clinical applications of angiogenesis. Nature 473 298-307. (doi:10.1038/nature10144)
26. Carter HB, Albertsen PC, Barry MJ, Etzioni R, Freedland SJ, Greene KL, Holmberg L, Kantoff P, Konety BR, Murad MH et al. 2013 Early detection of prostate cancer: AUA Guideline. Journal of Urology 190 419-426. (doi:10.1016/j.juro.2013.04.119)
27. Cash J, Korchnak A, Gorman J, Tandon Y & Fraizer G 2007 VEGF transcription and mRNA stability are altered by WT1 not DDS(R384W) expression in LNCaP cells. Oncology Reports 17 1413-1419.
28. Chakravarty D, Sboner A, Nair SS, Giannopoulou E, Li R, Hennig S, Mosquera JM, Pauwels J, Park K, Kossai M et al. 2014 The oestrogen receptor a-regulated lncRNA NEAT1 is a critical modulator of prostate cancer. Nature Communications 5 5383. (doi:10.1038/ncomms6383)
29. Chang SH, Lu YC, Li X, Hsieh WY, Xiong Y, GhoshM, Evans T, Elemento O & Hla T 2013 Antagonistic function of the RNA-binding protein HuR and miR-200b in post-transcriptional regulation of vascular endothelial growth factor-A expression and angiogenesis. Journal of Biological Chemistry 288 4908-4921. (doi:10.1074/jbc.M112.423871)
30. Chen J, De S, Brainard J & Byzova TV 2004Metastatic properties of prostate cancer cells are controlled by VEGF. Cell Communication & Adhesion 11 1-11. (doi:10.1080/15419060490471739)
31. Cheng X & Blumenthal RM 2010 Coordinated chromatin control: structural and functional linkage of DNA and histone methylation. Biochemistry 49 2999-3008. (doi:10.1021/bi100213t)
32. Cheng ML & Fong L 2014 Beyond sipuleucel-T: immune approaches to treating prostate cancer. Current Treatment Options in Oncology 15 115-126. (doi:10.1007/s11864-013-0267-z)
33. Chiaverotti T, Couto SS, Donjacour A, Mao JH, Nagase H, Cardiff RD, Cunha GR & Balmain A 2008 Dissociation of epithelial and neuroendocrine carcinoma lineages in the transgenic adenocarcinoma of mouse prostate model of prostate cancer. American Journal of Pathology 172 236-246. (doi:10.2353/ajpath.2008.070602)
34. Claffey KP, Shih SC, Mullen A, Dziennis S, Cusick JL, Abrams KR, Lee SW& Detmar M 1998 Identification of a human VPF/VEGF 3′ untranslated region mediating hypoxia-induced mRNA stability. Molecular Biology of the Cell 9 469-481. (doi:10.1091/mbc.9.2.469)
35. Cohen T, Nahari D, Cerem LW, Neufeld G & Levi BZ 1996 Interleukin 6 induces the expression of vascular endothelial growth factor. Journal of Biological Chemistry 271 736-741. (doi:10.1074/jbc.271.2.736)
36. Coles LS, Bartley MA, Bert A, Hunter J, Polyak S, Diamond P, Vadas MA & Goodall GJ 2004 A multi-protein complex containing cold shock domain (Y-box) and polypyrimidine tract binding proteins forms on the vascular endothelial growth factor mRNA. Potential role in mRNA stabilization. European Journal of Biochemistry 271 648-660. (doi:10.1111/j.1432-1033.2003.03968.x)
37. Cuzick J, Thorat MA, Andriole G, Brawley OW, Brown PH, Culig Z, Eeles RA, Ford LG, Hamdy FC, Holmberg L et al. 2014 Prevention and early detection of prostate cancer. Lancet. Oncology 15 e484-e492. (doi:10.1016/S1470-2045(14)70211-6)
38. DadianiM, Seger D, Kreizman T, Badikhi D, Margalit R, Eilam R & Degani H 2009 Estrogen regulation of vascular endothelial growth factor in breast cancer in vitro and in vivo: the role of estrogen receptor a and c-Myc. Endocrine-Related Cancer 16 819-834. (doi:10.1677/ERC-08-0249)
39. Daehlin L, Damber JE, Selstam G & Bergman B 1985 Testosterone-induced decrement of prostatic vascular resistance in rats is reversed by estrogens. Prostate 6 351-359. (doi:10.1002/pros.2990060404)
40. Dahut WL, Madan RA, Karakunnel JJ, Adelberg D, Gulley JL, Turkbey IB, Chau CH, Spencer SD, Mulquin M, Wright J et al. 2013 Phase II clinical trial of cediranib in patients with metastatic castration-resistant prostate cancer. BJU International 111 1269-1280. (doi:10.1111/j.1464-410X.2012.11667.x)
41. Dai J, Kitagawa Y, Zhang J, Yao Z, Mizokami A, Cheng S, Nor J, McCauley LK, Taichman RS & Keller ET 2004 Vascular endothelial growth factor contributes to the prostate cancer-induced osteoblast differentiation mediated by bone morphogenetic protein. Cancer Research 64 994-999.(doi:10.1158/0008-5472.CAN-03-1382)
42. Dawson MA & Kouzarides T 2012 Cancer epigenetics: from mechanism to therapy. Cell 150 12-27. (doi:10.1016/j.cell.2012.06.013)
43. Debes JD, Sebo TJ, Lohse CM, Murphy LM, Haugen DA & Tindall DJ 2003 p300 in prostate cancer proliferation and progression. Cancer Research 63 7638-7640.
44. Dibbens JA, Miller DL, Damert A, Risau W, Vadas MA & Goodall GJ 1999 Hypoxic regulation of vascular endothelial growth factor mRNA stability requires the cooperation of multiple RNA elements. Molecular Biology of the Cell 10 907-919. (doi:10.1091/mbc.10.4.907)
45. Draisma G, Etzioni R, Tsodikov A, Mariotto A, Wever E, Gulati R, Feuer E & de Koning H 2009 Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. Journal of the National Cancer Institute 101 374-383. (doi:10.1093/jnci/djp001)
46. Duque JL, Loughlin KR, Adam RM, Kantoff PW, Zurakowski D&Freeman MR 1999 Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer. Urology 54 523-527. (doi:10.1016/S0090-4295(99)00167-3)
47. Eisermann K, Broderick CJ, Bazarov A, Moazam MM & Fraizer GC 2013 Androgen up-regulates vascular endothelial growth factor expression in prostate cancer cells via an Sp1 binding site. Molecular Cancer 12 7.(doi:10.1186/1476-4598-12-7)
48. El Kaffas A, Giles A & Czarnota GJ 2013 Dose-dependent response of tumor vasculature to radiation therapy in combination with Sunitinib depicted by three-dimensional high-frequency power Doppler ultrasound. Angiogenesis 16 443-454. (doi:10.1007/s10456-012-9329-2)
49. Eswaraka J, Giddabasappa A, Han G, Lalwani K, Eisele K, Feng Z, Affolter T, Christensen J & Li G 2014 Axitinib and crizotinib combination therapy inhibits bone loss in a mouse model of castration resistant prostate cancer. BMC Cancer 14 742. (doi:10.1186/1471-2407-14-742)
50. Fan L, Wu Q, Xing X, Wei Y & Shao Z 2012 MicroRNA-145 targets vascular endothelial growth factor and inhibits invasion and metastasis of osteosarcoma cells. Acta Biochimica et Biophysica Sinica 44 407-414. (doi:10.1093/abbs/gms019)
51. Fellows A, Griffin ME, Petrella BL, Zhong L, Parvin-Nejad FP, Fava R, Morganelli P, Robey RB & Nichols RC 2012 AUF1/hnRNP D represses expression of VEGF in macrophages. Molecular Biology of the Cell 23 1414-1422. (doi:10.1091/mbc.E11-06-0545)
52. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, Forman D & Bray F 2013 Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. European Journal of Cancer 49 1374-1403. (doi:10.1016/j.ejca.2012.12.027)
53. Folkman J 1971 Tumor angiogenesis: therapeutic implications. New England Journal of Medicine 285 1182-1186. (doi:10.1056/NEJM197108122850711)
54. Folkman J, Merler E, Abernathy C & Williams G 1971 Isolation of a tumor factor responsible for angiogenesis. Journal of Experimental Medicine 133 275-288. (doi:10.1084/jem.133.2.275)
55. Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD & Semenza GL 1996 Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Molecular and Cellular Biology 16 4604-4613.
56. Gabrilovich DI, Chen HL, Girgis KR, Cunningham HT, Meny GM, Nadaf S, Kavanaugh D & Carbone DP 1996 Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nature Medicine 2 1096-1103. (doi:10.1038/nm1096-1096)
57. Geretti E, van Meeteren LA, Shimizu A, Dudley AC, Claesson-Welsh L & Klagsbrun M 2010 A mutated soluble neuropilin-2 B domain antagonizes vascular endothelial growth factor bioactivity and inhibits tumor progression. Molecular Cancer Research 8 1063-1073. (doi:10.1158/1541-7786.MCR-10-0157)
58. Gingrich JR, Barrios RJ, Morton RA, Boyce BF, DeMayo FJ, Finegold MJ, Angelopoulou R, Rosen JM & Greenberg NM 1996 Metastatic prostate cancer in a transgenic mouse. Cancer Research 56 4096-4102.
59. Gingrich JR, Barrios RJ, KattanMW, NahmHS, FinegoldMJ&GreenbergNM 1997 Androgen-independent prostate cancer progression in the TRAMP model. Cancer Research 57 4687-4691.
60. Gingrich JR, Barrios RJ, Foster BA & Greenberg NM 1999 Pathologic progression of autochthonous prostate cancer in the TRAMP model. Prostate Cancer and Prostatic Diseases 2 70-75. (doi:10.1038/sj.pcan.4500296)
61. GodoyA, Montecinos VP, Gray DR, Sotomayor P, Yau JM, VethanayagamRR, Singh S, Mohler JL & Smith GJ 2011 Androgen deprivation induces rapid involution and recovery of human prostate vasculature. American Journal of Physiology. Endocrinology and Metabolism 300 E263-E275. (doi:10.1152/ajpendo.00210.2010)
62. Goel HL, Chang C, Pursell B, Leav I, Lyle S, Xi HS, Hsieh CC, Adisetiyo H, Roy-Burman P, Coleman IM et al. 2012 VEGF/neuropilin-2 regulation of Bmi-1 and consequent repression of IGF-IR define a novel mechanism of aggressive prostate cancer. Cancer Discovery 2 906-921. (doi:10.1158/2159-8290.CD-12-0085)
63. Goldberg-Cohen I, Furneauxb H & Levy AP 2002 A 40-bp RNA element that mediates stabilization of vascular endothelial growth factor mRNA by HuR. Journal of Biological Chemistry 277 13635-13640. (doi:10.1074/jbc.M108703200)
64. Grabowska MM, DeGraff DJ, Yu X, Jin RJ, Chen Z, Borowsky AD &Matusik RJ 2014 Mouse models of prostate cancer: picking the best model for the question. Cancer Metastasis Reviews 33 377-397. (doi:10.1007/s10555-013-9487-8)
65. Gray DR, Huss WJ, Yau JM, Durham LE, Werdin ES, Funkhouser WK & Smith GJ 2004 Short-term human prostate primary xenografts an in vivo model of human prostate cancer vasculature and angiogenesis. Cancer Research 64 1712-1721. (doi:10.1158/0008-5472.CAN-03-2700)
66. Gray MJ, Zhang J, Ellis LM, Semenza GL, Evans DB, Watowich SS &Gallick GE 2005 HIF-1a, STAT3, CBP/p300 and Ref-1/APE are components of a transcriptional complex that regulates Src-dependent hypoxia-induced expression of VEGF in pancreatic and prostate carcinomas. Oncogene 24 3110-3120. (doi:10.1038/sj.onc.1208513)
67. Green MM, Hiley CT, Shanks JH, Bottomley IC, West CM, Cowan RA & Stratford IJ 2007 Expression of vascular endothelial growth factor (VEGF) in locally invasive prostate cancer is prognostic for radiotherapy outcome. International Journal of Radiation Oncology, Biology, Physics 67 84-90. (doi:10.1016/j.ijrobp.2006.08.077)
68. Grothey A, Van CutsemE, Sobrero A, Siena S, Falcone A, YchouM, Humblet Y, Bouche O, Mineur L, Barone C et al. 2013 Regorafenib monotherapy for previously treatedmetastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381 303-312. (doi:10.1016/S0140-6736(12)61900-X)
69. Hamdollah ZadehMA, AminEM, Hoareau-Aveilla C, DomingoE, Symonds KE, Ye X, HeesomKJ, Salmon A, D'Silva O & Betteridge KB 2015 Alternative splicing of TIA-1 in human colon cancer regulates VEGF isoform expression, angiogenesis, tumour growth and bevacizumab resistance. Molecular Oncology 9 167-178. (doi:10.1016/j.molonc.2014.07.017)
70. Harper SJ & Bates DO 2008 VEGF-A splicing: the key to anti-angiogenic therapeutics? Nature Reviews. Cancer 8 880-887. (doi:10.1038/nrc2505)
71. Heemers HV, Sebo TJ, Debes JD, Regan KM, Raclaw KA, Murphy LM, Hobisch A, Culig Z & Tindall DJ 2007 Androgen deprivation increases p300 expression in prostate cancer cells. Cancer Research 67 3422-3430. (doi:10.1158/0008-5472.CAN-06-2836)
72. Heidenreich A, Abrahamsson PA, Artibani W, Catto J, Montorsi F, Van Poppel H, Wirth M & Mottet N 2013 Early detection of prostate cancer: European Association of Urology recommendation. European Urology 64 347-354. (doi:10.1016/j.eururo.2013.06.051)
73. Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F et al. 2014 EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013. European Urology 65 124-137. (doi:10.1016/j.eururo.2013.09.046)
74. Horoszewicz JS, Leong SS, Chu TM, Wajsman ZL, Friedman M, Papsidero L, Kim U, Chai LS, Kakati S, Arya SK et al. 1980 The LNCaP cell line-a new model for studies on human prostatic carcinoma. Progress in Clinical and Biological Research 37 115-132.
75. Hrouda D, Nicol DL & Gardiner RA 2003 The role of angiogenesis in prostate development and the pathogenesis of prostate cancer. Urological Research 30 347-355. (doi:10.1007/s00240-002-0287-9)
76. Huez I, Creancier L, Audigier S, Gensac MC, Prats AC & Prats H 1998 Two independent internal ribosome entry sites are involved in translation initiation of vascular endothelial growth factor mRNA. Molecular and Cellular Biology 18 6178-6190.
77. Huggins C & Hodges C 1941 Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Research 1 293-297.
78. Humphrey PA 2012 Histological variants of prostatic carcinoma and their significance. Histopathology 60 59-74. (doi:10.1111/j.1365-2559.2011.04039.x)
79. Huntzinger E & Izaurralde E 2011 Gene silencing by microRNAs: contributions of translational repression and mRNA decay. Nature Reviews. Genetics 12 99-110. (doi:10.1038/nrg2936)
80. Ikeda E, Achen MG, Breier G & Risau W 1995 Hypoxia-induced transcriptional activation and increased mRNA stability of vascular endothelial growth factor in C6 glioma cells. Journal of Biological Chemistry 270 19761-19766. (doi:10.1074/jbc.270.34.19761)
81. Jang SK, Krausslich HG, Nicklin MJ, Duke GM, Palmenberg AC&Wimmer E 1988 A segment of the 50 nontranslated region of encephalomyocarditis virus RNA directs internal entry of ribosomes during in vitro translation. Journal of Virology 62 2636-2643.
82. Kahl P, Gullotti L, Heukamp LC, Wolf S, Friedrichs N, Vorreuther R, Solleder G, Bastian PJ, Ellinger J, Metzger E et al. 2006 Androgen receptor coactivators lysine-specific histone demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate cancer recurrence. Cancer Research 66 11341-11347. (doi:10.1158/0008-5472.CAN-06-1570)
83. Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF & Jones LW 1979 Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Investigative Urology 17 16-23.
84. Kaplan RN, Riba RD, Zacharoulis S, Bramley AH, Vincent L, Costa C, MacDonald DD, Jin DK, Shido K, Kerns SA et al. 2005 VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 438 820-827. (doi:10.1038/nature04186)
85. Kaplan-Lefko PJ, Chen TM, Ittmann MM, Barrios RJ, Ayala GE, Huss WJ, Maddison LA, Foster BA & Greenberg NM 2003 Pathobiology of autochthonous prostate cancer in a pre-clinical transgenic mouse model. Prostate 55 219-237. (doi:10.1002/pros.10215)
86. Kashyap V, Ahmad S, NilssonEM, Helczynski L, Kenna S, Persson JL, Gudas LJ & Mongan NP 2013 The lysine specific demethylase-1 (LSD1/KDM1A) regulates VEGF-A expression in prostate cancer. Molecular Oncology 7 555-566. (doi:10.1016/j.molonc.2013.01.003)
87. Kaur S, Chang T, Singh SP, Lim L, Mannan P, Garfield SH, Pendrak ML, Soto-Pantoja DR, Rosenberg AZ, Jin S et al. 2014 CD47 signaling regulates the immunosuppressive activity of VEGF in T cells. Journal of Immunology 193 3914-3924. (doi:10.4049/jimmunol.1303116)
88. King PH 2000 RNA-binding analyses of HuC and HuD with the VEGF and c-myc 3′-untranslated regions using a novel ELISA-based assay. Nucleic Acids Research 28 E20. (doi:10.1093/nar/28.7.e20)
89. Kitagawa Y, Dai J, Zhang J, Keller JM, Nor J, Yao Z & Keller ET 2005 Vascular endothelial growth factor contributes to prostate cancer-mediated osteoblastic activity. Cancer Research 65 10921-10929. (doi:10.1158/0008-5472.CAN-05-1809)
90. Klezovitch O, Chevillet J, Mirosevich J, Roberts RL, Matusik RJ & Vasioukhin V 2004 Hepsin promotes prostate cancer progression and metastasis. Cancer Cell 6 185-195. (doi:10.1016/j.ccr.2004.07.008)
91. Kooistra SM & Helin K 2012 Molecular mechanisms and potential functions of histone demethylases. Nature Reviews. Molecular Cell Biology 13 297-311. (doi:10.1038/nrm3327)
92. KrejsgaardT, Vetter-KauczokCS, WoetmannA, LovatoP, LabudaT, EriksenKW, Zhang Q, Becker JC & Odum N 2006 Jak3-and JNK-dependent vascular endothelial growth factor expression in cutaneous T-cell lymphoma. Leukemia 20 1759-1766. (doi:10.1038/sj.leu.2404350)
93. Lambrechts D, Storkebaum E, Morimoto M, Del-Favero J, Desmet F, Marklund SL, Wyns S, Thijs V, Andersson J, van Marion I et al. 2003 VEGF is a modifier of amyotrophic lateral sclerosis inmice and humans and protects motoneurons against ischemic death. Nature Genetics 34 383-394. (doi:10.1038/ng1211)
94. Levy AP, Levy NS & Goldberg MA 1996 Post-transcriptional regulation of vascular endothelial growth factor by hypoxia. Journal of Biological Chemistry 271 2746-2753. (doi:10.1074/jbc.271.5.2746)
95. Lorente D & De Bono JS 2014 Molecular alterations and emerging targets in castration resistant prostate cancer. European Journal of Cancer 50 753-764. (doi:10.1016/j.ejca.2013.12.004)
96. Maes C, Kobayashi T, Selig MK, Torrekens S, Roth SI, Mackem S, CarmelietG & Kronenberg HM 2010 Osteoblast precursors, but not mature osteoblasts, move into developing and fractured bones along with invading blood vessels. Developmental Cell 19 329-344. (doi:10.1016/j.devcel.2010.07.010)
97. Mangoni M, Vozenin MC, Biti G& Deutsch E 2012 Normal tissues toxicities triggered by combined anti-angiogenic and radiation therapies: hurdles might be ahead. British Journal of Cancer 107 308-314. (doi:10.1038/bjc.2012.236)
98. Martin BJ 2013 Inhibiting vasculogenesis after radiation: a new paradigm to improve local control by radiotherapy. Seminars in Radiation Oncology 23 281-287. (doi:10.1016/j.semradonc.2013.05.002)
99. Masumori N, Thomas TZ, Chaurand P, Case T, Paul M, Kasper S, Caprioli RM, Tsukamoto T, Shappell SB & Matusik RJ 2001 A probasin-large T antigen transgenic mouse line develops prostate adenocarcinoma and neuroendocrine carcinoma with metastatic potential. Cancer Research 61 2239-2249.
100. Mavrou A, Brakspear K, Hamdollah-Zadeh M, Damodaran G, Babaei-Jadidi R, Oxley J, Gillatt DA, Ladomery MR, Harper SJ, Bates DO et al. 2014 Serine-arginine protein kinase 1 (SRPK1) inhibition as a potential novel targeted therapeutic strategy in prostate cancer. Oncogene [in press]. (doi:10.1038/onc.2014.360)
101. Mellman I, Coukos G & Dranoff G 2011 Cancer immunotherapy comes of age. Nature 480 480-489. (doi:10.1038/nature10673)
102. Metzger E, Wissmann M, Yin N, Muller JM, Schneider R, Peters AH, Gunther T, Buettner R & Schule R 2005 LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription. Nature 437 436-439. (doi:10.1038/nature04020)
103. Midy V & Plouet J 1994 Vasculotropin/vascular endothelial growth factor induces differentiation in cultured osteoblasts. Biochemical and Biophysical Research Communications 199 380-386. (doi:10.1006/bbrc.1994.1240)
104. Miller DL, Dibbens JA, Damert A, Risau W, Vadas MA & Goodall GJ 1998 The vascular endothelial growth factor mRNA contains an internal ribosome entry site. FEBS Letters 434 417-420. (doi:10.1016/S0014-5793(98)01025-4)
105. Molife LR, Omlin A, Jones RJ, Karavasilis V, Bloomfield D, Lumsden G, Fong PC, Olmos D, O'Sullivan JM, Pedley I et al. 2014 Randomized phase II trial of nintedanib, afatinib and sequential combination in castration-resistant prostate cancer. Future Oncology 10 219-231. (doi:10.2217/fon.13.250)
106. Montecinos VP, Godoy A, Hinklin J, Vethanayagam RR & Smith GJ 2012 Primary xenografts of human prostate tissue as a model to study angiogenesis induced by reactive stroma. PLoS ONE 7 e29623. (doi:10.1371/journal.pone.0029623)
107. Montico F, Kido LA, Hetzl AC & Cagnon VH 2014 Prostatic angiogenic responses in late life: antiangiogenic therapy influences and relation with the glandular microenvironment in the transgenic adenocarcinoma of mouse prostate (TRAMP) model. Prostate 75 484-499. (doi:10.1002/pros.22934)
108. Morris MJ, Negishi Y, Pazsint C, Schonhoft JD & Basu S 2010 An RNA G-quadruplex is essential for cap-independent translation initiation in human VEGF IRES. Journal of the American Chemical Society 132 17831-17839. (doi:10.1021/ja106287x)
109. Nowak DG, Woolard J, AminEM, KonopatskayaO, SaleemMA, ChurchillAJ, Ladomery MR, Harper SJ & Bates DO 2008 Expression of pro-and antiangiogenic isoforms of VEGF is differentially regulated by splicing and growth factors. Journal of Cell Science 121 3487-3495. (doi:10.1242/jcs.016410)
110. Nowak DG, Amin EM, Rennel ES, Hoareau-Aveilla C, Gammons M, Damodoran G, Hagiwara M, Harper SJ, Woolard J, Ladomery MR et al. 2010 Regulation of vascular endothelial growth factor (VEGF) splicing from pro-angiogenic to anti-angiogenic isoforms: a novel therapeutic strategy for angiogenesis. Journal of Biological Chemistry 285 5532-5540. (doi:10.1074/jbc.M109.074930)
111. Ogita S, Tejwani S, Heilbrun L, Fontana J, Heath E, Freeman S, Smith D, Baranowski K & Vaishampayan U 2012 Pilot phase II trial of bevacizumab monotherapy in nonmetastatic castrate-resistant prostate cancer. ISRN Oncology 2012 242850. (doi:10.5402/2012/242850)
112. Oltean S, Gammons M, Hulse R, Hamdollah-Zadeh M, Mavrou A, Donaldson L, Salmon AH, Harper SJ, Ladomery MR & Bates DO 2012 SRPK1 inhibition in vivo: modulation of VEGF splicing and potential treatment for multiple diseases. Biochemical Society Transactions 40 831-835. (doi:10.1042/BST20120051)
113. Onesto C, Berra E, Grepin R & Pages G 2004 Poly(A)-binding protein-interacting protein 2, a strong regulator of vascular endothelial growth factor mRNA. Journal of Biological Chemistry 279 34217-34226. (doi:10.1074/jbc.M400219200)
114. Pang X, Wu Y, Wu Y, Lu B, Chen J, Wang J, Yi Z, QuW& Liu M 2011a (K)-Gossypol suppresses the growth of human prostate cancer xenografts via modulating VEGF signaling-mediated angiogenesis. Molecular Cancer Therapeutics 10 795-805. (doi:10.1158/1535-7163.MCT-10-0936)
115. Pang X, Zhang L, Lai L, Chen J, Wu Y, Yi Z, Zhang J, Qu W, Aggarwal BB & Liu M 2011b 10-acetoxychavicol acetate suppresses angiogenesismediated human prostate tumor growth by targeting VEGF-mediated Src-FAK-Rho GTPase-signaling pathway. Carcinogenesis 32 904-912. (doi:10.1093/carcin/bgr052)
116. Pei Z, Lin D, Song X, Li H & Yao H 2008 TLR4 signaling promotes the expression of VEGF and TGFβ1 in human prostate epithelial PC3 cells induced by lipopolysaccharide. Cellular Immunology 254 20-27. (doi:10.1016/j.cellimm.2008.06.007)
117. Pelletier J & Sonenberg N 1988 Internal initiation of translation of eukaryotic mRNA directed by a sequence derived from poliovirus RNA. Nature 334 320-325. (doi:10.1038/334320a0)
118. Perillo B, Ombra MN, Bertoni A, Cuozzo C, Sacchetti S, Sasso A, Chiariotti L, Malorni A, Abbondanza C & Avvedimento EV 2008 DNA oxidation as triggered by H3K9me2 demethylation drives estrogen-induced gene expression. Science 319 202-206. (doi:10.1126/science.1147674)
119. Pettaway CA, Pathak S, Greene G, Ramirez E, Wilson MR, Killion JJ&Fidler JJ 1996 Selection of highly metastatic variants of different human prostatic carcinomas using orthotopic implantation in nude mice. Clinical Cancer Research 2 1627-1636.
120. Pinthus JH, Waks T, Schindler DG, Harmelin A, Said JW, Belldegrun A, Ramon J & Eshhar Z 2000 WISH-PC2: a unique xenograft model of human prostatic small cell carcinoma. Cancer Research 60 6563-6567.
121. Porta C, Giglione P, Liguigli W & Paglino C 2015 Dovitinib (CHIR258, TKI258): structure, development and preclinical and clinical activity. Future Oncology 11 39-50. (doi:10.2217/fon.14.208)
122. Presnell SC, Werdin ES, Maygarden S, Mohler JL & Smith GJ 2001 Establishment of short-term primary human prostate xenografts for the study of prostate biology and cancer. American Journal of Pathology 159 855-860. (doi:10.1016/S0002-9440(10)61761-0)
123. Punnen S, Cooperberg MR, D'Amico AV, Karakiewicz PI, Moul JW, Scher HI, Schlomm T & Freedland SJ 2013 Management of biochemical recurrence after primary treatment of prostate cancer: a systematic review of the literature. European Urology 64 905-915. (doi:10.1016/j.eururo.2013.05.025)
124. Qi WX, Tang LN, He AN, Shen Z & Yao Y 2011 The role of vandetanib in the second-line treatment for advanced non-small-cell-lung cancer: ametaanalysis of four randomized controlled trials. Lung 189 437-443. (doi:10.1007/s00408-011-9332-1)
125. Rahman MM, Miyamoto H, Lardy H & Chang C 2003 Inactivation of androgen receptor coregulator ARA55 inhibits androgen receptor activity and agonist effect of antiandrogens in prostate cancer cells. PNAS 100 5124-5129. (doi:10.1073/pnas.0530097100)
126. Roskoski R Jr 2007 Vascular endothelial growth factor (VEGF) signaling in tumor progression. Critical Reviews in Oncology/Hematology 62 179-213. (doi:10.1016/j.critrevonc.2007.01.006)
127. Rotili D, Tomassi S, Conte M, Benedetti R, Tortorici M, Ciossani G, Valente S, Marrocco B, Labella D, Novellino E et al. 2014 Pan-histone demethylase inhibitors simultaneously targeting Jumonji C and lysine-specific demethylases display high anticancer activities. Journal of Medicinal Chemistry 57 42-55. (doi:10.1021/jm4012802)
128. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND et al. 2012 Increased survival with enzalutamide in prostate cancer after chemotherapy. New England Journal of Medicine 367 1187-1197. (doi:10.1056/NEJMoa1207506)
129. Semenas J, Allegrucci C, Boorjian SA, Mongan NP & Persson JL 2012 Overcoming drug resistance and treating advanced prostate cancer. Current Drug Targets 13 1308-1323. (doi:10.2174/138945012802429615)
130. Setlur SR, Mertz KD, Hoshida Y, Demichelis F, Lupien M, Perner S, Sboner A, Pawitan Y, Andren O, Johnson LA et al. 2008 Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. Journal of the National Cancer Institute 100 815-825. (doi:10.1093/jnci/djn150)
131. Sfar S, Hassen E, Saad H, Mosbah F & Chouchane L 2006 Association of VEGF genetic polymorphisms with prostate carcinoma risk and clinical outcome. Cytokine 35 21-28. (doi:10.1016/j.cyto.2006.07.003)
132. Shah RB, Mehra R, Chinnaiyan AM, Shen R, Ghosh D, Zhou M, Macvicar GR, Varambally S, Harwood J, Bismar TA et al. 2004 Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Research 64 9209-9216. (doi:10.1158/0008-5472.CAN-04-2442)
133. Sharma NL, Massie CE, Ramos-Montoya A, Zecchini V, Scott HE, Lamb AD, MacArthur S, Stark R, Warren AY, Mills IG et al. 2013 The androgen receptor induces a distinct transcriptional program in castrationresistant prostate cancer in man. Cancer Cell 23 35-47. (doi:10.1016/j.ccr.2012.11.010)
134. Shih SC & Claffey KP 1999 Regulation of human vascular endothelial growth factor mRNA stability in hypoxia by heterogeneous nuclear ribonucleoprotein L. Journal of Biological Chemistry 274 1359-1365. (doi:10.1074/jbc.274.3.1359)
135. Shima DT, Deutsch U & D'Amore PA 1995 Hypoxic induction of vascular endothelial growth factor (VEGF) in human epithelial cells is mediated by increases in mRNA stability. FEBS Letters 370 203-208. (doi:10.1016/0014-5793(95)00831-S)
136. Siegel RL, Miller KD & Jemal A 2015 Cancer statistics, 2015. CA: A Cancer Journal for Clinicians 65 5-29. (doi:10.3322/caac.21254)
137. Small AC & Oh WK 2012 Bevacizumab treatment of prostate cancer. Expert Opinion on Biological Therapy 12 1241-1249. (doi:10.1517/14712598.2012.704015)
138. Smith MR, Sweeney CJ, Corn PG, Rathkopf DE, Smith DC, Hussain M, George DJ, Higano CS, Harzstark AL, Sartor AO et al. 2014 Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion study. Journal of Clinical Oncology 32 3391-3399. (doi:10.1200/JCO.2013.54.5954)
139. Sohn EJ, Won G, Lee J, Lee S & Kim SH 2015 Upregulation of miRNA3195 and miRNA374b mediates the anti-angiogenic properties of melatonin in hypoxic PC-3 prostate cancer cells. Journal of Cancer 6 19-28. (doi:10.7150/jca.9591)
140. Sridhar SS, Joshua AM, Gregg R, Booth CM, Murray N, Golubovic J, Wang L, Harris P& Chi KN 2014 A phase II study of GW786034 (pazopanib) with or without bicalutamide in patients with castration-resistant prostate cancer. Clinical Genitourinary Cancer 13 124-129. (doi:10.1016/j.clgc.2014.06.001)
141. Sterling JA, Edwards JR, Martin TJ & Mundy GR 2011 Advances in the biology of bone metastasis: how the skeleton affects tumor behavior. Bone 48 6-15. (doi:10.1016/j.bone.2010.07.015)
142. Stewart SB & Boorjian SA 2014 Radical prostatectomy in high-risk and locally advanced prostate cancer: Mayo Clinic perspective. Urologic Oncology [in press]. (doi:10.1016/j.urolonc.2014.10.003)
143. Street J, BaoM, deGuzman L, Bunting S, Peale FV Jr, Ferrara N, Steinmetz H, Hoeffel J, Cleland JL, Daugherty A et al. 2002 Vascular endothelial growth factor stimulates bone repair by promoting angiogenesis and bone turnover. PNAS 99 9656-9661. (doi:10.1073/pnas.152324099)
144. Sweeney P, Karashima T, Kim SJ, Kedar D, Mian B, Huang S, Baker C, Fan Z, Hicklin DJ, Pettaway CA et al. 2002 Anti-vascular endothelial growth factor receptor 2 antibody reduces tumorigenicity and metastasis in orthotopic prostate cancer xenografts via induction of endothelial cell apoptosis and reduction of endothelial cell matrix metalloproteinase type 9 production. Clinical Cancer Research 8 2714-2724.
145. Szczyrba J, Loprich E, Wach S, Jung V, Unteregger G, Barth S, Grobholz R, Wieland W, Stohr R, Hartmann A et al. 2010 The microRNA profile of prostate carcinoma obtained by deep sequencing. Molecular Cancer Research 8 529-538. (doi:10.1158/1541-7786.MCR-09-0443)
146. Szczyrba J, Nolte E, Hart M, Doll C, Wach S, Taubert H, Keck B, Kremmer E, Stohr R, Hartmann A et al. 2013 Identification of ZNF217, hnRNP-K, VEGF-A and IPO7 as targets for microRNAs that are downregulated in prostate carcinoma. International Journal of Cancer 132 775-784. (doi:10.1002/ijc.27731)
147. Tannock IF, Fizazi K, Ivanov S, Karlsson CT, Flechon A, Skoneczna I, Orlandi F, Gravis G, Matveev V, Bavbek S et al. 2013 Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial. Lancet. Oncology 14 760-768. (doi:10.1016/S1470-2045(13)70184-0)
148. Tay Y, Zhang J, Thomson AM, Lim B & Rigoutsos I 2008 MicroRNAs to Nanog, Oct4 and Sox2 coding regions modulate embryonic stem cell differentiation. Nature 455 1124-1128. (doi:10.1038/nature07299)
149. Thalmann GN, Anezinis PE, Chang SM, Zhau HE, Kim EE, Hopwood VL, Pathak S, von Eschenbach AC & Chung LW 1994 Androgenindependent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Research 54 2577-2581.
150. Tombal B, Alcaraz A, James N, Valdagni R & Irani J 2014 Can we improve the definition of high-risk, hormone naive, non-metastatic prostate cancer? BJU International 113 189-199. (doi:10.1111/bju.12469)
151. Van Der Kelen K, Beyaert R, Inze D & De Veylder L 2009 Translational control of eukaryotic gene expression. Critical Reviews in Biochemistry and Molecular Biology 44 143-168. (doi:10.1080/10409230902882090)
152. Vuky J, PhamHT, Warren S, Douglass E, Badiozamani K, Madsen B, Hsi A & Song G 2012 Phase II study of long-term androgen suppression with bevacizumab and intensity-modulated radiation therapy (IMRT) in high-risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics 82 e609-e615. (doi:10.1016/j.ijrobp.2011.09.002)
153. Walczak R, Joseph SB, Laffitte BA, Castrillo A, Pei L & Tontonoz P 2004 Transcription of the vascular endothelial growth factor gene in macrophages is regulated by liver X receptors. Journal of Biological Chemistry 279 9905-9911. (doi:10.1074/jbc.M310587200)
154. Wan X, Corn PG, Yang J, Palanisamy N, Starbuck MW, Efstathiou E, Tapia EM, Zurita AJ, Aparicio A, Ravoori MK et al. 2014 Prostate cancer cell-stromal cell crosstalk via FGFR1 mediates antitumor activity of dovitinib in bone metastases. Science Translational Medicine 6 252ra122. (doi:10.1126/scitranslmed.3009332)
155. Wang S, Gao J, Lei Q, Rozengurt N, Pritchard C, Jiao J, Thomas GV, Li G, Roy-Burman P, Nelson PS et al. 2003 Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell 4 209-221. (doi:10.1016/S1535-6108(03)00215-0)
156. Wang Q, Li W, Zhang Y, Yuan X, Xu K, Yu J, Chen Z, Beroukhim R, Wang H, Lupien M et al. 2009 Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell 138 245-256. (doi:10.1016/j.cell.2009.04.056)
157. Wegiel B, Bjartell A, Ekberg J, Gadaleanu V, Brunhoff C & Persson JL 2005 A role for cyclin A1 in mediating the autocrine expression of vascular endothelial growth factor in prostate cancer. Oncogene 24 6385-6393. (doi:10.1038/sj.onc.1208795)
158. Wegiel B, Bjartell A, Tuomela J, Dizeyi N, Tinzl M, Helczynski L, Nilsson E, Otterbein L, Härkönen P & Persson JL 2008 Multiple cellular mechanisms related to cyclin A1 in prostate cancer invasion and metastasis. Journal of the National Cancer Institute 100 1022-1036. (doi:10.1093/jnci/djn214)
159. Weiner AB, Patel SG & Eggener SE 2015 Pathologic outcomes for low-risk prostate cancer after delayed radical prostatectomy in the United States. Urologic Oncology 33 164.e11-164.e17. (doi:10.1016/j.urolonc.2014.12.012)
160. Wong SY, Haack H, Crowley D, Barry M, Bronson RT & Hynes RO 2005 Tumor-secreted vascular endothelial growth factor-C is necessary for prostate cancer lymphangiogenesis, but lymphangiogenesis is unnecessary for lymph node metastasis. Cancer Research 65 9789-9798. (doi:10.1158/0008-5472.CAN-05-0901)
161. Woolard J, Wang WY, Bevan HS, Qiu Y, Morbidelli L, Pritchard-Jones RO, Cui TG, Sugiono M, Waine E, Perrin R et al. 2004 VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression. Cancer Research 64 7822-7835. (doi:10.1158/0008-5472.CAN-04-0934)
162. Wu J, Richer J, Horwitz KB & Hyder SM 2004 Progestin-dependent induction of vascular endothelial growth factor in human breast cancer cells: preferential regulation by progesterone receptor B. Cancer Research 64 2238-2244. (doi:10.1158/0008-5472.CAN-03-3044)
163. Wu X, Gong S, Roy-Burman P, Lee P & Culig Z 2013 Current mouse and cell models in prostate cancer research. Endocrine-Related Cancer 20 R155-R170. (doi:10.1530/ERC-12-0285)
164. Yonou H, Yokose T, Kamijo T, Kanomata N, Hasebe T, Nagai K, Hatano T, Ogawa Y & Ochiai A 2001 Establishment of a novel species-and tissuespecificmetastasis model of human prostate cancer in humanized nonobese diabetic/severe combined immunodeficient mice engrafted with human adult lung and bone. Cancer Research 61 2177-2182.
165. Yu J, Mani RS, Cao Q, Brenner CJ, Cao X, Wang X, Wu L, Li J, Hu M, Gong Y et al. 2010 An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell 17 443-454. (doi:10.1016/j.ccr.2010.03.018)
166. Yue X, Wang P, Xu J, Zhu Y, Sun G, Pang Q & Tao R 2012MicroRNA-205 functions as a tumor suppressor in human glioblastoma cells by targeting VEGF-A. Oncology Reports 27 1200-1206. (doi:10.3892/or.2011.1588)
167. Yun H, Lee M, Kim SS & Ha J 2005 Glucose deprivation increases mRNA stability of vascular endothelial growth factor through activation of AMP-activated protein kinase in DU145 prostate carcinoma. Journal of Biological Chemistry 280 9963-9972. (doi:10.1074/jbc.M412994200)
168. Zhou Z, Flesken-Nikitin A, Corney DC, Wang W, Goodrich DW, Roy-Burman P & Nikitin AY 2006 Synergy of p53 and Rb deficiency in a conditional mouse model for metastatic prostate cancer. Cancer Research 66 7889-7898. (doi:10.1158/0008-5472.CAN-06-0486)
169. Zhuang HQ, Yuan ZY & Wang P 2014 Research progress on the mechanisms of combined bevacizumab and radiotherapy. Recent Patents on Anti-Cancer Drug Discovery 9 129-134.